Reporting satisfactory growth in both Healthcare Services Segment and Medical Devices Segment, the Group's core businesses, total turnover amounted to HK$210,882,000, with 30% growth compared to the previous interim period. Excluding the non-cash and non-operating loss of HK$41,526,000 due to volatility in global financial markets which led to the decline in value of the Group's securities and previously issued convertible notes, and non-operating gain of HK$34,653,000 due to gain on disposal of partial interest in an associate, the adjusted profit attributable to equity shareholders of the Company should amount to HK$83,518,000, representing 7% increase over the previous corresponding period.
Healthcare Services SegmentHealthcare Services Segment, which consists of the Group's Hospital Management Business and GM-Medicare, the specialised medical insurance administration business, accounted for 30% of total turnover compared to 23% in the previous reporting period, reflecting the inclusion of revenue contribution from the newly acquired Shanghai East International Medical Centre ("SEIMC").
Several key events took place during the interim period, including the expansion of Daopei Hospital in Beijing and the acquisition of SEIMC, a joint-venture with the renowned Shanghai East Hospital serving mostly the premium healthcare services market, setting the stage for this segment to become the key growth and revenue driver for the Group going forward. Hence revenues from the hospital management operations reached HK$62,747,000 during the interim period with 65% increase relative to the previous interim period.
Contribution from China Cord Blood Corporation (or "CCBC," CO.US), the Group's associate company, continued to report impressive revenue growth of 20% for the first half of the fiscal year relative
|SOURCE Golden Meditech Holdings Limited|
Copyright©2010 PR Newswire.
All rights reserved